For patients with RAS and BRAF wild-type, especially those with primary tumors located in the left colon or rectum, cetuximab has demonstrated superiority over bevacizumab in terms of early tumor shrinkage (ETS), depth of tumor response (DPR), disease control rate (DCR), and overall survival (OS) (4, 5). This evidence concerns the gene BRAF and neoplasm.